~ AlphaMD Welcome to AlphaMD, your trusted online provider for testosterone therapy
Semaglutide Nephroprotection: FLOW Trial Insights The FLOW study assessed semaglutides capacity to delay CKD progression and reduce kidney/heart death
adultsaround 9% of the total populationwill be taking a GLP-1 drugs, pushing the total market value over $100 billion
When the medications reach the brain and bind to receptors in the habenula, they reduce the compulsive pull behind behaviors like overeating often described by patients as food noise. Thats one reason why GLP-1s are now being studied as potential tools for treating or preventing substance use disorders
And a few even enjoy the vividness, finding it strangely artistic or insightful: "Its what I imagine a mushroom trip might be like wild!" - Obvious_Razzmatazz22 Whats clear is that nightmares are a genuine, community-reported experience-not universal, not dangerous for most, but undeniably impactful